Selected Publications on Influenza Vaccine Effectiveness
Arden NH, Patriarca PA, and Kendal AP. Options for the Control of Influenza: Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. UCLA Symposia on Molecular and Cellular Biology 1985; 36: 155-168. Print.
Ashkenazi S, Vertruyen A, Arístegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25(10):870-9.
Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009; 200(12):1861-9.
Bragstad K, Emborg HD, Fischer TK, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13-A rapid epidemiological and virological assessment. Eurosurveillance 2013; 18(6).Top of Page
Edmondson W.P., Rothenberg R, White P.W. et al. A Comparison of Subcutaneous, Nasal, and Combined Influenza Vaccination. II. Protection Against Natural Challenge. American Journal of Epidemiology 1971; 93(6):481-486.
Ferdinands JM, Olsho LEW, Agan AA, et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis. 2014. Advance access (online).
Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006; 25(10):860-9.
Fleming DH, Watson JM, Nicholas S, et al. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiol Infect 1995; 115:581-9.
Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA1994; 272(21):1661-5.Top of Page
Hak E, Buskens E, Van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: The PRISMA study. Arch Intern Med 2005; 165:274-80.
Hak E, Verheij TJ, Grobbee DE, et al. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health 2002; 56:951-5.
Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20(7-8):1240-1247.
Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomized controlled trial. BMJ 2006; 333(7581):1241.
Herrera GA, Iwane MK, Cortese M, et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine 2007; 25:54-60.
Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003; 290(12):1608-16.
Jackson ML, Nelson JC, Weiss NS, et al. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008; 372:398-405.Top of Page
Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010; 10:71.
Kissling E et al. “I-Move towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-center case-control study in Europe, 2008-9.” Euro Surveill.2009; 14(44):1-7.
Kissling E. et al. Low and decreasing vaccine effectiveness against Influenza A (H3) in 2011-12 among vaccination target groups in Europe: Results from the I-Move Multicentre Case-Control Study. Euro Surveill 2013; 18(5).
Macintosh V, Tastad k, Eick-Cost A. Mid-season influenza vaccine effectiveness 2011-2012: A Department of Defense global, Laboratory-based, Influenza Surveillance System case-control study estimate. Vaccine 2013; SO264-410X.
McMenamim J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-influenza infection in primary care in the United Kingdom: Mid-Season analysis 2012/13. Eurosurveillance 2013; 18(5).Top of Page
Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001; 20(8):733-40.
Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130:397-403.
Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21:2207-17.
Nichol KL, Margolis J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis. 2001; 184:665-70.
Nordin J, Mullooly J, Poblese S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J. Infect. Dis 2001; 184:665-70.Top of Page
Oshitani H, Saito R, Seki N et al. Influenza Vaccination Levels and Influenza-Like Illness in Long-Term-Care Facilities for Elderly People in Niigata, Japan, During an Influenza A (H3N2) Epidemic. Infection Control and Hospital Epidemiology 2000; 21(11):728-730.
Pebody RG, Andrews N, Mcmenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: Evidence of waning intra-seasonal protection. Eurosurveillance 2013; 18(5).
Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain: a test-negative, hospital-based, case-control study. Vaccine 2010; 28:7460-7.Top of Page
Talbot HK, Griffin, MR, Chen Q, et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J. Infect Dis 2011; 203:500-8.
Talbot HK, Zhu Y, Chen Q, et al. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. Clin Infect Dis. 2013; 56(12): 1774-7.
Thompson MG, Li DK, Shifflett P, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis. 2014; 58(4): 449-57.
Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999; 18(9-10):899-906.Top of Page
- Page last reviewed: October 23, 2013
- Page last updated: March 27, 2014
- Content source: